Humana Inc (NYSE:HUM) hit a new 52-week high during trading on Thursday . The company traded as high as $378.99 and last traded at $377.56, with a volume of 232947 shares trading hands. The stock had previously closed at $373.86.
A number of research analysts have commented on HUM shares. Mizuho restated a “buy” rating and issued a $405.00 target price on shares of Humana in a research note on Friday. UBS Group boosted their target price on Humana from $321.00 to $406.00 and gave the company a “neutral” rating in a research note on Thursday, January 23rd. SunTrust Banks restated a “hold” rating and issued a $370.00 target price on shares of Humana in a research note on Tuesday, December 17th. ValuEngine downgraded Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, December 4th. Finally, Argus boosted their target price on Humana to $370.00 and gave the company a “buy” rating in a research note on Wednesday, November 20th. One analyst has rated the stock with a sell rating, four have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $380.50.
The company has a market cap of $46.75 billion, a P/E ratio of 18.72, a P/E/G ratio of 1.41 and a beta of 0.95. The firm has a 50 day moving average price of $360.28 and a 200-day moving average price of $316.11. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.83 and a current ratio of 1.82.
Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, February 5th. The insurance provider reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.20 by $0.08. The company had revenue of $16.30 billion during the quarter, compared to the consensus estimate of $16.15 billion. Humana had a return on equity of 20.89% and a net margin of 4.17%. The firm’s revenue was up 15.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.65 EPS. On average, sell-side analysts forecast that Humana Inc will post 18.65 EPS for the current fiscal year.
In related news, insider Timothy S. Huval sold 7,373 shares of the business’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $348.60, for a total transaction of $2,570,227.80. Following the completion of the transaction, the insider now owns 14,548 shares of the company’s stock, valued at approximately $5,071,432.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Elizabeth D. Bierbower sold 14,655 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $351.42, for a total value of $5,150,060.10. Following the transaction, the insider now directly owns 21,985 shares of the company’s stock, valued at approximately $7,725,968.70. The disclosure for this sale can be found here. In the last quarter, insiders have sold 45,294 shares of company stock valued at $15,894,412. 0.54% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Endurance Wealth Management Inc. lifted its position in shares of Humana by 354.5% during the 3rd quarter. Endurance Wealth Management Inc. now owns 100 shares of the insurance provider’s stock worth $26,000 after purchasing an additional 78 shares during the last quarter. Evoke Wealth LLC acquired a new position in shares of Humana during the 3rd quarter worth about $26,000. Quest Capital Management Inc. ADV acquired a new position in shares of Humana during the 3rd quarter worth about $30,000. Penserra Capital Management LLC acquired a new position in Humana in the 3rd quarter valued at approximately $31,000. Finally, Lighthouse Financial Advisors Inc. acquired a new position in Humana in the 4th quarter valued at approximately $31,000. 94.44% of the stock is owned by institutional investors and hedge funds.
About Humana (NYSE:HUM)
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.